1. Home
  2. DTCX vs GANX Comparison

DTCX vs GANX Comparison

Compare DTCX & GANX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Datacentrex Inc. Common Stock

DTCX

Datacentrex Inc. Common Stock

N/A

Current Price

$2.02

Market Cap

80.7M

Sector

Technology

ML Signal

N/A

Logo Gain Therapeutics Inc.

GANX

Gain Therapeutics Inc.

HOLD

Current Price

$1.72

Market Cap

88.6M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
DTCX
GANX
Founded
N/A
2017
Country
United States
United States
Employees
N/A
N/A
Industry
EDP Services
Biotechnology: Pharmaceutical Preparations
Sector
Technology
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
80.7M
88.6M
IPO Year
2021
2021

Fundamental Metrics

Financial Performance
Metric
DTCX
GANX
Price
$2.02
$1.72
Analyst Decision
Strong Buy
Analyst Count
0
4
Target Price
N/A
$7.50
AVG Volume (30 Days)
288.0K
456.7K
Earning Date
04-13-2026
05-13-2026
Dividend Yield
N/A
N/A
EPS Growth
8.00
31.46
EPS
N/A
N/A
Revenue
$2,446.00
$55,180.00
Revenue This Year
N/A
N/A
Revenue Next Year
N/A
N/A
P/E Ratio
N/A
N/A
Revenue Growth
N/A
N/A
52 Week Low
$1.51
$1.53
52 Week High
$3.80
$4.34

Technical Indicators

Market Signals
Indicator
DTCX
GANX
Relative Strength Index (RSI) 46.35 42.57
Support Level $1.74 $1.71
Resistance Level $2.31 $2.22
Average True Range (ATR) 0.29 0.09
MACD -0.06 -0.02
Stochastic Oscillator 14.07 1.67

Price Performance

Historical Comparison
DTCX
GANX

About DTCX Datacentrex Inc. Common Stock

Datacentrex Inc is a digital infrastructure and capital deployment company that owns and operates Scrypt compute assets and evaluates strategic transactions across asset-backed operating businesses. Its current operating platform is centered on owned and operated Scrypt-based proof-of-work compute deployed through third-party colocation facilities. Datacentrex monetizes this compute through hashrate marketplace mechanisms and manages a treasury of digital assets and cash in a manner intended to preserve capital and support opportunistic, accretive deployment. The company's operations are principally operated remotely at various data centers throughout the United States.

About GANX Gain Therapeutics Inc.

Gain Therapeutics Inc is a clinical-stage biotechnology company developing novel small-molecule therapeutics to treat diseases across several therapeutic areas, including central nervous system (CNS) disorders, lysosomal storage disorders (LSDs), metabolic disorders, and other diseases that can be targeted through protein degradation, such as oncology. The Company's clinical stage product candidate, GT-02287, is being developed for the treatment of Parkinson's disease with and without GBA1 mutations. The Company generated an extensive preclinical data package providing evidence of the mechanism of action.

Share on Social Networks: